Table 1 Socio-demographic, treatment, WHO clinical stage and CD4 cell counts of study participants
Characteristics | All patients n (%) | Patients with oral lesions n (%)* | χ2-value | p-value** |
|---|---|---|---|---|
Gender | Â | Â | Â | Â |
Male | 165 (31.0) | 63 (38.2) | 0.17 | 0.68 |
Female | 367 (69.0) | 147 (40.1) | Â | Â |
Age (Years) | Â | Â | Â | Â |
Children 2–17 | 51 (9.6) | 21 (41.2) | 0.68 | 0.88 |
Adults 18 – 67 | 481 (90.4) | 189 (39.3) |  |  |
Smoking habit | Â | Â | Â | Â |
Current | 20 (3.8) | 14 (70) | 8.17 | 0.02 |
Stopped | 17 (3.2) | 7 (41.2) | Â | Â |
Never | 495 (93.0) | 189 (38.2) | Â | Â |
Alcohol consumption | Â | Â | Â | Â |
Current | 31 (5.8) | 10 (32.3) | Â | Â |
Stopped | 37 (7.0) | 16 (43.2) | 0.90 | 0.64 |
Never | 464 (87.2) | 184 (39.6) | Â | Â |
Traditional medicine | Â | Â | Â | Â |
Yes | 62 (11.7) | 25 (40.3) | 0.17 | 0.68 |
No | 470 (88.3) | 183 (38.9) | Â | Â |
Antiretroviral therapy | Â | Â | Â | Â |
Without therapy | 234 (44.0) | 127 (54.3) | 38.30 | 0.00 |
HAART therapy | 298 (56.0) | 83 (27.9) | Â | Â |
Antiretroviral types | Â | Â | Â | Â |
Stav/Lamiv/Nev | 229 (76.8) | 9 (12.9) | 2.96 | 0.57 |
Stav/Lamiv/Eff | 26 (8.7) | 10 (38.5) | Â | Â |
Zido/Lamiv/Eff | 32 (10.7) | 11 (34.4) | Â | Â |
Zido/Lamiv/Nev | 10 (3.4) | 2 (20.0) | Â | Â |
Abac/Lop/Didan | 1 (0.3) | 0 (0) | Â | Â |
WHO HIV clinical stage | Â | Â | Â | Â |
Stage I | 70 (13.2) | 9 (12.9) | Â | Â |
Stage II | 204 (38.3) | 38 (18.6) | 120.93 | 0.00 |
Stage III | 169 (31.8) | 101 (59.8) | Â | Â |
Stage IV | 89 (16.7) | 62 (69.7) | Â | Â |
CD4 + cell count (cells/mm 3 ) | Â | Â | Â | Â |
> 500 | 46 (8.6) | 10 (21.7) | Â | Â |
200–500 | 164 (30.8) | 33 (20.5) | 52.45 | 0.00 |
< 200 | 322 (60.5) | 167 (31.9) | Â | Â |
Total number of patients | 532 (100.) | 210 (39.5) | Â | Â |